Agilon Health (NYSE:AGL) Trading 8.5% Higher – Should You Buy?

Agilon Health, Inc. (NYSE:AGL) shot up 8.5% during trading on Friday . The stock traded as high as $96.08 and last traded at $96.4180. Approximately 54,065 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 357,666 shares. The stock had previously closed at $88.90.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on AGL shares. Deutsche Bank Aktiengesellschaft raised shares of Agilon Health from a “hold” rating to a “buy” rating and raised their target price for the stock from $33.00 to $49.00 in a report on Thursday, May 7th. Wall Street Zen upgraded Agilon Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. TD Cowen reaffirmed a “hold” rating and issued a $55.00 target price (up from $17.00) on shares of Agilon Health in a research report on Monday, May 11th. Robert W. Baird set a $116.00 target price on Agilon Health in a research note on Thursday, August 6th. Finally, Benchmark reissued a “buy” rating and set a $140.00 price target (up from $95.00) on shares of Agilon Health in a report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Agilon Health presently has a consensus rating of “Hold” and an average target price of $86.18.

Agilon Health Stock Up 9.3%

The company has a market cap of $1.63 billion, a price-to-earnings ratio of -6.81 and a beta of 3.01. The stock has a 50-day simple moving average of $106.88 and a 200-day simple moving average of $58.04. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.07.

Agilon Health (NYSE:AGL) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.90. The business had revenue of $1.49 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Agilon Health had a negative net margin of 3.92% and a negative return on equity of 119.38%. As a group, analysts predict that Agilon Health, Inc. will post -2.95 EPS for the current year.

Institutional Investors Weigh In On Agilon Health

A number of institutional investors have recently added to or reduced their stakes in AGL. Rubicon Founders LLC acquired a new position in shares of Agilon Health during the 2nd quarter valued at $11,290,448,000. Great Lakes Advisors LLC acquired a new position in Agilon Health during the second quarter worth about $702,000. Bank of New York Mellon Corp lifted its holdings in Agilon Health by 9.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 35,336 shares of the company’s stock valued at $3,787,000 after acquiring an additional 3,074 shares during the last quarter. Alpine Global Management LLC acquired a new stake in Agilon Health in the 4th quarter valued at about $84,000. Finally, Invesco Ltd. boosted its position in shares of Agilon Health by 30.7% during the 4th quarter. Invesco Ltd. now owns 1,004,266 shares of the company’s stock valued at $692,000 after purchasing an additional 235,951 shares in the last quarter.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.